Sagent Turns Generic Injectable Shortages Into Business Opportunity

The specialty generic manufacturer has a facility dedicated to producing shortage drugs, a seemingly endless commercial opportunity given the development, regulatory and reimbursement challenges in the sterile injectable space.

Sagent Pharmaceuticals Inc., a high-growth drug manufacturer playing in the generic injectable space, is focusing on drug shortages as one area of expertise and benefiting commercially.

The company, which operates a sterile manufacturing plant in Chengdu, China dedicated to shortage drugs, launched its first product out of the plant

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Focus On Asia